Chelating Agents for Neurodegenerative Diseases

Authors: J. Ward, R.; T. Dexter, D.; R. Crichton, R.

Source: Current Medicinal Chemistry, Volume 19, Number 17, June 2012 , pp. 2760-2772(13)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

It has become apparent in the last years that metal ion homeostasis and its dysfunction which results in increased accumulation in brain, notably of copper, iron and zinc, may be associated with a number of neurodegenerative diseases, such that chelation therapy may be one therapeutic option. We briefly outline chelators currently available together with strategies to develop new chelators capable of crossing the blood-brain-barrier. The homeostasis of iron in brain together with changes in brain iron with ageing are reviewed as well as the role of iron in Parkinson's disease, and the potential of chelation therapy in PD. Copper and zinc homeostasis in brain and ageassociated changes are then outlined, along with a discussion of the possible involvement of Zn, Cu and Fe in Alzheimer's disease. We conclude with a brief summary of chelation therapy in AD.

Keywords: chelation; neurodegeneration; iron; copper; zinc; homeostasis; blood-brain-barrier; Parkinson's; therapy in AD; Alzheimer's disease

Document Type: Research article

DOI: http://dx.doi.org/10.2174/092986712800609689

Affiliations: 1: Universite Catholique de Louvain, 1348 Louvain-la-Neuve, Belgium.

Publication date: 2012-06-01

More about this publication?

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.